XT
APRE icon

XTX Topco’s Aprea Therapeutics APRE Stock Holding History

XTX Topco’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.48K Buy
+10,565
New +$8.81K ﹤0.01% 4040
2026
Q1 		– Sell
-24,304
Closed -$20.7K – 3814
2025
Q4 		$20.7K Buy
+24,304
New +$29.8K ﹤0.01% 3054
2022
Q1 		– Sell
-1,364
Closed -$78K – 664
2021
Q4 		$78K Buy
+1,364
New +$120K 0.04% 505

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco's APRE Position: Q2 2026 in Review

XTX Topco opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 10,565 shares worth $8.48K. The stake represents ﹤0.01% of the portfolio and ranks #4040 among its holdings. This is a return to the name: XTX Topco previously reported a position in APRE as recently as Q4 2025.

XTX Topco first reported a position in APRE in Q4 2021 and has held it in 3 quarters since. The position peaked at $78K in Q4 2021. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • XTX Topco held 10,565 shares of Aprea Therapeutics worth $8.48K as of Q2 2026.
  • Aprea Therapeutics was a new XTX Topco position in Q2 2026.
  • Aprea Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #4040 holding.
  • XTX Topco first reported a position in Aprea Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • XTX Topco's Aprea Therapeutics position peaked at $78K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.